Evidence map›Paper›PMID 34789274›Full record

ArticleJournal of nanobiotechnology2021

Dye-loaded mesoporous polydopamine nanoparticles for multimodal tumor theranostics with enhanced immunogenic cell death.

Ying Tian, Muhammad Rizwan Younis, Yuxia Tang, Xiang Liao, Gang He, Shouju Wang, Zhaogang Teng, Peng Huang, Longjiang Zhang, Guangming Lu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Ying Tian *Department of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, People's Republic of China.
Muhammad Rizwan Younis *Marshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, 518060, People's Republic of China.
Yuxia Tang *Department of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, People's Republic of China.
Xiang LiaoDepartment of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, People's Republic of China.
Gang HeMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, 518060, People's Republic of China.
Shouju WangDepartment of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, People's Republic of China.
Zhaogang TengKey Laboratory for Organic Electronics and Information Displays & Institute of Advanced Materials, Nanjing University of Posts & Telecommunications, Nanjing, 210023, People's Republic of China.
Peng HuangMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, 518060, People's Republic of China. peng.huang@szu.edu.cn.ORCID http://orcid.org/0000-0003-3651-7813
Longjiang ZhangDepartment of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, People's Republic of China. kevinzhlj@163.com.
Guangming LuDepartment of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, People's Republic of China. cjr.luguangming@vip.163.com.
Nanjing General Hospital of Nanjing Military Command · CNShenzhen University Health Science Center · CNNanjing Medical University · CNNanjing University of Posts and Telecommunications · CN

Funding

basic research program of shenzhen JCYJ20180507182413022basic research program of shenzhen JCYJ20200109105620482innovative research group project of the national natural science foundation of china 81530054innovative research group project of the national natural science foundation of china 81601556innovative research group project of the national natural science foundation of china 81901806innovative research group project of the national natural science foundation of china 81971681national key r&d program of china 2020YFA0908800shenzhen science and technology program KQTD20190929172538530
6 · The paper itself

Abstract

backgroundTumor phototherapy especially photodynamic therapy (PDT) or photothermal therapy (PTT), has been considered as an attractive strategy to elicit significant immunogenic cell death (ICD) at an optimal tumor retention of PDT/PTT agents. Heptamethine cyanine dye (IR-780), a promising PDT/PTT agent, which can be used for near-infrared (NIR) fluorescence/photoacoustic (PA) imaging guided tumor phototherapy, however, the strong hydrophobicity, short circulation time, and potential toxicity in vivo hinder its biomedical applications. To address this challenge, we developed mesoporous polydopamine nanoparticles (MPDA) with excellent biocompatibility, PTT efficacy, and PA imaging ability, facilitating an efficient loading and protection of hydrophobic IR-780.

resultsThe IR-780 loaded MPDA (IR-780@MPDA) exhibited high loading capacity of IR-780 (49.7 wt%), good physiological solubility and stability, and reduced toxicity. In vivo NIR fluorescence and PA imaging revealed high tumor accumulation of IR-780@MPDA. Furthermore, the combined PDT/PTT of IR-780@MPDA could induce ICD, triggered immunotherapeutic response to breast tumor by the activation of cytotoxic T cells, resulting in significant suppression of tumor growth in vivo.

conclusionThis study demonstrated that the as-developed compact and biocompatible platform could induce combined PDT/PTT and accelerate immune activation via excellent tumor accumulation ability, offering multimodal tumor theranostics with negligible systemic toxicity.

Indexed as

Antineoplastic AgentsCarbocyaninesFluorescent DyesAnimalsCell Line, TumorCell SurvivalFemaleIndolesMammary Neoplasms, AnimalMiceNanoparticlesPhototherapyPolymersTheranostic NanomedicineTissue DistributionAntineoplastic AgentsCarbocyaninesFluorescent Dyesheptamethine cyanine dyeIndolespolydopaminePolymersImmunogenic cell deathIR-780Mesoporous polydopamine nanoparticlesPhotodynamic therapyPhotothermal therapy

Identifiers

PMID34789274
PMCPMC8596951
OpenAlexW3214310034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.